The CAR T-cell therapy market size was valued at $2.6 billion in 2022 and is estimated to reach $35.9 billion by 2032, exhibiting a CAGR of 28.5% by 2032.

Unlike CAR-T cells, NK cells don’t need genetic modification to recognize a specific threat — they act broadly without ...

Immunocytokines are a promising area of research in cancer therapy, combining the targeting capabilities of monoclonal antibodies with the therapeutic effects of cytokines. This innovative ...

Caregiving can take many forms, often requiring a profound shift in daily life. While navigating a disease is an immense ...

Merck seems to have identified cytokines as a fertile ground for exploration, as the Synthekine deal follows its earlier $1.9 billion takeover of Pandion Therapeutics, which is developing a ...

A research team at the Medical University of Vienna led by Maria Sibilia has investigated a new combination therapy against cancer.

Penn Medicine is one of the first institutions to develop FDA-approved CAR T-cell therapies. This therapy is currently ...

San Francisco confirmed that a child in the city became the first case of H5N1. A panel of biotech leaders discussed what ...

A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.

Researchers at MedUni Vienna have developed a combination therapy using systemic interferon-I and topical imiquimod.

Both photodynamic therapy (PDT) and immunotherapy are two of the biggest areas of cancer therapy with the potential to revolutionize healthcare. PDT conveys ...

NKure Therapeutics, a Bengaluru-based cell and gene therapy start-up, is trying to address this problem by working on ...